Graves' Ophthalmopathy Market Seen Growing 9% CAGR to 2036 as Viridian's LUMVOA Widens Competition
Updated
Updated · PR Newswire · Jul 29
Graves' Ophthalmopathy Market Seen Growing 9% CAGR to 2036 as Viridian's LUMVOA Widens Competition
3 articles · Updated · PR Newswire · Jul 29
Summary
USD 3.5 billion in 2025—the Graves' ophthalmopathy market across the seven major markets is forecast to expand at a 9% CAGR through 2036, according to a new DelveInsight report.
LUMVOA's June 2026 FDA approval is a key catalyst because Viridian's drug is labeled for both active and chronic thyroid eye disease, expanding the treatable population and sharpening competition with TEPEZZA.
About 2.4 million prevalent cases were recorded in the 7MM in 2025, including roughly 1.03 million diagnosed cases in the United States, the largest single market.
Pipeline candidates including Viridian's elegrobart, Sling's linsitinib, Amgen's AMG 732 and Roche's satralizumab are expected to push the market toward more convenient subcutaneous and oral targeted therapies.
The outlook reflects a broader shift from steroids, surgery and off-label biologics toward disease-specific IGF-1R-targeted treatments as diagnosis improves and autoimmune thyroid disorders become more common.